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Abstract
Background: There are differences in the prevalence and severity of diseases between males, females not taking
hormonal contraceptives (non-HC females) and females taking hormonal contraceptives (HC females). The aim of
this study was to identify sex-specific differences in the metabolome and its relation to components of the
metabolic syndrome in a young adult population.
Methods: The subjects analysed are from the 20-year follow-up of the Western Australian Pregnancy Cohort (Raine)
Study. Two hundred fifteen plasma metabolites were analysed in 1021 fasted plasma samples by a targeted liquid
chromatography coupled to tandem mass spectrometry (LC-MS/MS) metabolomics approach. Principal component
analysis between males (n = 550), non-HC females (n = 199) and HC females (n = 269) was applied. Regression
analysis with a sex × metabolite concentration interaction was performed on components of the MetS, namely
waist circumference, systolic blood pressure, and plasma HDL-C, triglycerides and glucose concentration, as
outcome to select the significant metabolites of the interaction. Those selected metabolites were used as predictors
in a sex group stratified analysis to compare the different β coefficients and therefore the sex group-dependent
associations.
Results: Principal component analysis between males, non-HC females, and HC females showed a general
discriminating trend between males and HC females. One hundred twenty-seven metabolites were significantly
different between males and non-HC females, whereas 97 differed between non-HC females and HC females. Males
and non-HC females mainly differed in sphingomyelin, lyso-phosphatidylcholine, acyl-carnitine and amino acid
species, whilst non-HC females and HC females mainly differed in phosphatidylcholine, lyso-phosphatidylcholine
and acyl-carnitine concentrations. Forty-one metabolites (phosphatidylcholines, sphingomyelines, lyso-
phosphatidylcholine) were significantly differently associated with the MetS factors in the different groups.
Conclusions: We have shown clear differences between plasma metabolite concentrations in males, and HC or
non-HC females, especially in lyso-phosphatidylcholine, sphingomyelin and phosphatidylcholine, which have been
shown to associate with obesity in other studies. The association of these metabolites differed between sexes with
components of the metabolic syndrome, which means that development of diseases like obesity and diabetes may
differ between the sexes. Our findings highlight the importance of considering sex differences when conducting a
metabolomics study and the need to account for the effect of HC usage in females in future studies.
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Background
There is increasing evidence from epidemiological studies
that sex and oral contraceptive use in females modulate
the development and the severity of cardiovascular disease
[1–4]. For example, men are more likely to develop coron-
ary heart diseases than women, especially women prior to
menopause, but the risk of developing stroke and heart
failure is higher in women [1]. Similarly, more females
than males are overweight and obese in developing coun-
tries, whereas the opposite is found in developed countries
[5]. Since males and females differ in the development and
severity of obesity and insulin resistance, it is likely that
differences in their metabolism, as a result of genetic
effects and environmentally induced changes, may play an
important role.
Analysis of the metabolome of males and females
could provide insights into the sex-related differences of
progression and severity of cardiovascular diseases. Most
of the metabolomics studies to date have not stratified
analyses according to sex, most likely due to their small
sample size. Additionally, to our knowledge there are no
studies that have examined sex differences in metabolo-
mics and associated these with components of the meta-
bolic syndrome (MetS). In particular, the characterisation
of hormonal contraceptive usage in females with regards
to its potential effect on metabolomic changes is highly
underrepresented in current research, although a large
number of women have been using them since their
development in the 1960s [3].
This topic is of high relevance in the approach of
implementing sex-specific interventional strategies and
biomarker tests in future clinical settings. If biomarkers
are different between the sexes, the relevance of those
general biomarkers is questionable and also critical in
terms of false diagnosis.
The aim of this study was to examine the metabolome
of males and females at 20 years of age, including females
either using (HC) or not using hormonal contracep-
tives (non-HC), taking part in the Western Australian
Pregnancy Cohort (Raine) Study. The study related
potential differences in the metabolome to a number
of risk factors underlying the MetS [6].
Methods
Details on the Raine study have been reported previously
[7, 8]. Briefly, from 1989 to 1991, 2900 pregnant women
were enrolled in this prospective longitudinal cohort
study with the purpose to examine the effects of prenatal
ultrasound imaging on the offspring [8]. Two thousand
eight hundred sixty-eight live births were evaluated and
followed serially to 20 years of age. The present study
used cross-sectional data from the 20-year follow-up of
the cohort, which occurred between March 2010 and
April 2012 and included 87% of the active participants.
Ethics approval at the 20 year follow-up was obtained
from the University of Western Australia Human Re-
search Ethics Committee. Informed and written consent
was obtained from participants.
Serum insulin, glucose, lipids and liver function tests
were analysed using standardised protocols in the Path-
West Laboratory at Royal Perth Hospital, Perth, Western
Australia.
MetS components were the ones established by the
International Diabetes Federation, including central
obesity, raised systolic blood pressure (sysBP), fasting
raised triacylglycerol (TG), glucose, and reduced high
density lipoprotein cholesterol (HDL-C) [6]. HC use in
females was derived from a questionnaire and based on
current use of the oral contraceptive pill, implant, injec-
tion or any intrauterine HC-device and defined as a binary
variable yes/no.
Metabolomics measurements
Polar lipids (acyl-carnitines (acyl-Carn), diacyl-phosphatid
ylcholines (PCaa), acyl-alkyl-phosphatidylcholines (PCae),
sphingomyelines (SM), lyso-phosphatidylcholines (LPC/
LPCa), alkyl-linked lyso-phosphatidylcholines (LPCe)),
non-esterified fatty acids (NEFA) and amino acids (AA)
were measured as previously reported [7, 9, 10].
The Additional file 1 provides a detailed description of
the metabolomics methodology. Briefly, proteins of
plasma were precipitated by adding methanol including
internal standards. After centrifugation, the supernatant
was used for analyses by liquid chromatography (1200,
Agilent) coupled to triple quadrupole mass spectrometry
(4000QTRAP, Sciex). Metabolites were quantified by
comparison to external standards as μmol/L.
Potential confounding factors
Physical activity was assessed using the short form of the
International Physical Activity Questionnaire and asked
whether individuals performed more than 10 min of
moderate or vigorous physical activity, and time spent
walking or sitting in the last 7 days. The number of
days, hours and minutes was reported. We created a
categorical variable with “less than once a week”, “1 to
3 times” and “4 or more times” more than 10 min of
physical activity per week.
Sedentary behaviour assessment was based on hours
spent in front of a screen, including TV watching, play-
ing videogames, socializing and non-socializing activities
on the Internet.
Smoking cigarettes and drinking alcohol were used
as binary variables. Smoking was assessed by asking if
the participant was currently smoking. Alcohol con-
sumption was based on any alcohol consumption in
the last 7 days.
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Ethnicity was applied as a dichotomous variable of
Caucasian versus non-Caucasian.
Diet was based on dietary patterns as reported by
Ambrosini et al. and included three variables: a healthy
dietary pattern, a western dietary pattern and a dietary
misreporting variable of food intake to account for over,
under, or plausible dietary reporting [11].
Statistics
The software R (R Project for Statistical Computing,
http://www.r-project.org/, Version 3.0.2) was used for all
statistical analyses. To determine if the residuals were
normally distributed, we checked the diagnostic plots of
all the models. The R function crPlots from the car
package in R [12] was used to check if outliers influence
the linearity. We also assessed the boxplots for all vari-
ables used, leading to outlier exclusion. Together with our
sufficiently large sample size (Central Limit Theorem), the
model assumptions were met. Z-scores for each metabol-
ite within each batch have been calculated to account for
batch variation. A batch was defined as 81 samples
together with standards and 6 quality control samples. All
samples were measured in 15 batches.
We defined a three-level sex variable with the categories
males, non-HC females and HC females.
The analysis was divided in three parts. First of all, we
aimed at general sex differences.
General sex differences: principal component analysis
To determine whether the variance in the metabolo-
mics data could be explained in part by the sex categor-
ies, we applied principal component analysis (PCA),
which is used to find components that explain most of
the variance in the data. The components explaining
most of the variance (component 1 and component 2)
were plotted against each other to see if they showed
discriminating clusters for the sex categories. To assess
which metabolite groups drive that discrimination, the
loadings of the metabolite classes were depicted as
arrows in the same plot.
Sex differences in the associations with the components
of the MetS: analysis of variance
In the second analysis, we aimed to extract those metab-
olites that were significantly associated with at least one
of the components of the MetS, depending on the sex
variable.
Therefore, the metabolites that were significantly
different between the three levels of the sex variable
in association with the five continuous factors of the
MetS needed to be identified. This pre-selection of
metabolites was performed by applying a sex and me-
tabolite interaction variable into analysis of variance
(Anova) models with one of the five MetS indicators
per model as outcome adjusted for the above-mentioned
confounders. A significant interaction meant that the
association between the metabolite and the single MetS
factor was different depending on at least one of the three
sex categories. To indicate which sex groups differed, we
performed regression analysis to compare the three group
differences after the anova.
Regression models stratified by sex group
The third analysis aimed to determine if the effect size
of the metabolite in association with the single compo-
nent of the MetS was significantly different between the
three sex categories.
The metabolites that were significant in the interaction
with at least one of the factors associated with the MetS
were used to analyse if the effect sizes are significantly
different between the sex categories. Therefore, we
stratified the data into a male and non-HC and HC
female subset. In all analyses, one of the five factors
associated with the MetS was the outcome per model
and the identified metabolites the predictor, adjusted for
confounding variables.
The resulting standardized β coefficients were com-
pared between the three sex categories. Significance
for the difference of the β coefficients was tested by
applying a regression model with dummy variables
(male and non-HC female, HC female, each: yes (1),
no (0)), to determine if they were significantly differ-
ent to the reference category. This difference can be
interpreted as the difference in the association
between the metabolite and the outcome, if the re-
spective sex category is added. It is a way to perform
a significance test for the difference of β coefficients
in different categories (for an overview of the analysis
strategy, see Fig. 1).
To determine if the metabolites that showed up signifi-
cantly in the stratified groups were of any significance in
the general, unstratified population, we performed ana-
lyses with the whole data set, where a single one of the five
MetS indicators was the outcome and metabolite concen-
tration was the predictor, adjusted for the confounders
stated above (Additional file 1: Table S1).
We used false discovery rate as described by Benjamini
and Hochberg to account for multiple testing for the p
values [13]. This was performed using the p.adjust func-
tion of the R core package. The confidence intervals
were corrected for multiple testing using the formula
1— # of selected metabolites0:05# of all metabolites , according to Benjamini and
Yekutieli [14]. The correction procedure for multiple
testing was applied using the number of metabolites.
This approach was used, as the main aim of this study
was hypothesis generation, and the Bonferroni correction
is very restrictive in this regards.
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Results
The study characteristics of the participants are shown
in Table 1. Results for all models and metabolites can be
found in the Additional file 1: Table S1 which shows that
there were significant differences in the concentrations
of HDL-C, glucose and triglycerides, sysBP and waist
circumference (WC) between males and non-HC and
HC females.
General sex differences: principal component analysis
PCA (Figure Fig. 2) showed a clustering effect between
males and HC females, predominantly due to differences
in SM, PC and LPC.
In the regression, there were 127 metabolites signifi-
cantly different between males and non-HC females and
97 metabolites that differed significantly between HC
and non-HC females.
Males and HC females, however, significantly dif-
fered in 161 metabolites (Additional file 1: Table S2–
Table S4, Table 2).
Sex differences in the associations with components of
the MetS: analysis of variance
In the Anova, we found that 46 metabolites showed a
sex interaction with at least one component of the
MetS (Additional file 1: Table S5, group differences
Additional file 1: Table S5). These 46 metabolites
were included in the stratified analysis to examine the
standardized β values. All of the 46 metabolites were
significantly associated with the indicators of the
MetS in the unstratified analysis of the general Raine
study population.
Those metabolites were acyl-Carn C3:0, NEFA C24:5,
NEFA C26:1, PCaa C32:3, PCaa C34:1, PCaa C34:2, PCaa
C34:3, PCaa C36:0, PCaa C36:1, PCaa C36:2, PCaa C36:3,
PCaa C36:4, PCaa C38:0, PCaa C38:3, PCaa C38:4, PCaa
C38:5, PCaa C38:6 , PCaa C40:6, PCaa C40:4, PCaa C40:5,
PCae C36:1, PCae C38:0, PCae C40:0, PCae C40:6, SM
C36:0, SM C38:1, SM C38:2, SM C40:3, SM C40:4, SM
C40:5, SM C41:0, SM C42:4, SM C42:6, SM C44:6, LPCa
C16:0, LPCa C16:1, LPCa C18:0, LPCa C18:1, LPCa
C18:3, LPCa C20:3, LPCa C20:4, LPCa C20:5, LPCa
C22:5, LPCa C22:6, LPCe C18:0, and LPCe C18:1 (for sex
group differences: Table 3, for p values, β-coefficients and
confidence interval: Additional file 1: Table S6).
In regression models stratified by sex group, we
found that 41 of these metabolites had significantly dif-
ferent between-group β coefficients, whereas acyl-Carn
C3:0, PCaa C34:2, PCaa C40:4, SMa C38:2 and NEFA
C26:1 showed no significant difference (Additional file 1:
Table S5). None of the metabolites were significantly
different between the sex categories for all MetS factors.
Fig. 1 Overview of the analytical strategy
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Table 1 Study participant characteristics stratified by sex and hormonal contraceptive (HC) use
Females not taking HC Females taking HC Males p value
n (%) 199 (19.55) 269 (26.42) 550 (54.03)
Age (years; mean ± sd) Age (years;
mean ± sd) Age (years; mean ± sd)
20.1 (0.6) 20.01 (0.61) 20.07 (0.50)
Waist circumference (cm; mean ± sd) 78.63 (±13.64) 76.09 (±11.96) 82.46 (±11.25) <0.001a <0.001b <0.05c
Body mass index (BMI, kg/m2) 24.88 (6.09) 23.85 (6.09) 24.32 (4.17) 0.0504c
Glucose (mmol/L; mean ± sd) 4.87 (±0.38) 4.83 (±0.36) 5.05 (±0.44) <0.001a <0.001b
Triglycerides (mmol/L;mean ± sd) 0.85 (±0.38) 1.16 (±0.49) 1.08 (±0.56) <0.001a <0.05b <0.001c
HDL-C (mmol/L; mean ± sd) 1.41 (±0.32) 1.42 (±0.30) 1.23 (±0.26) <0.001a <0.001b
LDL-C (mmol/L; mean ± sd) 2.51 (±0.64) 2.59 (±0.62) 2.43 (±0.67) 0.001b
Systolic blood pressure
(mm Hg; mean ± sd)
110.92 (±11.69) 111.7 (±10.65) 123.2 (±12.4) <0.001a <0.001b
Diastolic blood pressure
(mm Hg; mean ± sd)
65.16 (±8.16) 65.74 (±7.35) 65.48 (±8.27)
Western diet (mean ± sd) -0.25 (±0.79) -0.4 (±0.68) 0.41 (±0.94) <0.001a <0.001b <0.05c
Healthy diet (mean ± sd) 0.01 (±0.84) -0.01 (±0.80) 0.03 (±0.96)
Misreporting (n/%) <0.01a <0.001b
Underreporting 77 (38.7) 116 (43.12) 131 (23.82)
Plausible reporting 80 (40.2) 109 (40.52) 222 (40.36)
Over-reporting 8 (4.02) 11 (4.09) 33 (6)
NA 34 (17.09) 33 (12.26) 164 (29.82)
Physical Activity (in the last 7 days, n/%) <0.001a <0.001b
Less than once 39 (20) 55 (20.45) 36 (6.55)
1 to 3 times 76 (38.19) 122 (45.35) 137 (24.91)
More than 4 59 (29.65) 73 (27.14) 244 (44.36)
NA 25 (12.56) 19 (7.06) 133 (24.18)
Sedentary behaviour (hours per day, n/%) <0.05a <0.05b
0 / 1 (0.37) /
1 26 (13.07) 42 (15.61) 37 (6.73)
2 80 (40.2) 113 (42.01) 204 (37.09)
3 47 (23.62) 74 (27.51) 142 (25.82)
4 24 (12.06) 21 (7.81) 41 (7.45)
NA 22 (11.06) 18 (6.69) 126 (22.91)
Smoking (currently, n/%)
No 154 (77.39) 217 (80.67) 355 (64.55)
Yes 23 (11.56) 33 (12.27) 68 (12.36)
NA 22 (11.06) 19 (7.06) 127 (23.09)
Alcohol consumption ((in the last 7
days, n/%)
<0.001a <0.01c
No 103 (51.76) 110 (40.89) 158 (28.37)
Yes 70 (35.18) 137 (50.93) 258 (46.91)
NA 26 (13.07) 22 (8.18) 134 (24.36)
Ethnicity (n/%)
Caucasian 159 (79.9) 234 (86.99) 452 (82.18)
Not Caucasian 34 (17.09) 33 (12.27) 84 (15.27)
NA 6 (3.02) 2 (0.74) 14 (2.55)
Data expressed as mean ± standard deviation · Superscript letters are statistical significance between groups (t test for continuous, Chi2 test for
categorial variables): a: male vs female, b: male vs hormonal, c: female vs hormonal
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For HDL, TAG and WC, LPCa C18:3 was significantly
different. LPCa C18:1, LPCa C20:4, LPCa C22:6 and SMa
C41:0 shared different associations depending on the sex
category for HDL and WC.
HDL and TAG had significant differences in the me-
tabolites LPCa C16:0, LPCa C18:0, LPCa C18:3, LPCe
C18:1, PCaa C34:1, PCaa C34:3, PCaa C38:3, PCaa
C38:4, SMa C36:0 and SMa C42:4 between the sex cat-
egories in common.
For HDL, LPCa C16:1, LPCa C20:3, LPCa C20:5, LPCa
C22:5, LPCe C18:0, NEFA C24:5, PCaa C38:0, PCaa
C38:6, PCaa C40:5, PCaa C40:6, PCae C40:0, PCae
C40:6 and SMa C42:6 were significantly different be-
tween males, hormonal contraceptive-taking females and
non-hormonal contraceptive-taking females.
TAG was significantly differently associated with PCaa
C32:3, PCaa C36:0, PCaa C36:1, PCaa C36:2, PCaa
C36:3, PCaa C36:4, PCaa C38:5, PCae C36:1, PCae
C38:0, SMa C38:1, SMa C40:3 and SMa C40:4 (Fig. 3).
Discussion
Our results show significant differences in the concen-
trations of metabolites in males, HC and non-HC fe-
males. In general, males have higher LPC and Carn
levels, and non-HC females have higher SM and PC
levels. HC females have higher NEFA concentrations
than non-HC females and males. The concentrations of
HDL-C, glucose and TG, sysBP and WC differed signifi-
cantly between males, HC and non-HC females and also
in their associations with metabolite concentrations.
Numerous epidemiological studies have shown the
prevalence of non-communicable diseases differs between
males and females, and it is well established that sex hor-
mones have a significant effect on certain diseases [1,
4]. In the field of metabolomics, however, there are
few studies addressing sex differences, and how they
affect the metabolome underlying diseases risk factors
[3, 15, 16]. Most of the metabolomics studies con-
ducted to date have either not taken potential sex dif-
ferences into account or have used males and females
in the same model. There are several studies showing
similar results as our study concerning the sex differ-
ences in metabolites [3, 15, 17]. However, to our
knowledge there is only one other study that has ex-
amined sex differences with respect to HC use and
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Table 2 Overview of number of significantly sex group
between different metabolite groups
Males vs hfemales Males vs nhfemales hfemales vs nhfemales
AA 15 ↑; 1 ↓ 15 ↑ ; 2↓ 4 ↑; 12 ↓
Carn 12 ↑ 11 ↑ 8 ↓
LPCa 13 ↑ 11 ↑ 13 ↓
LPCe 3 ↑ 3 ↑ 3 ↓
NEFA 2 ↑; 16 ↓ 3 ↑; 6↓ 6 ↑
PCaa 32 ↓ 20 ↓ 20 ↑; 2 ↓
PCae 3 ↑; 24 ↓ 1 ↑, 20↓ 8 ↑; 2 ↓
SM 1 ↑; 39 ↓ 1 ↑; 35↓ 15 ↑; 4↓
Arrows: ↑ meaning higher and ↓ meaning lower in the firstly mentiones group
in the group comparison
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metabolomics or that has investigated associations be-
tween metabolomics with different components of the
MetS [3, 15]. Given a significant number of women
of childbearing age are taking HC, this is a large
group that is not represented or analysed in many
clinical studies.
General sex differences
In the present study, we found higher WC in males than
females which supports data showing obese males have
more visceral adiposity than obese females [18]. Our data
supports the literature in showing that HDL-C concentra-
tions were higher in women than in men. Higher HDL-C is
known to associate with lower cardiovascular risk [17]. Pre-
vious reports have shown that lower HDL-C in males asso-
ciate with lower SM concentrations compared with that in
females [19]. Our data are in accordance with these results.
We found LPC and SM concentrations most differen-
tiating between males, non-HC and HC females. This
might be due to a suppression of lecithin cholesterol
acyltransferase (LCAT) activity by higher SM concentra-
tions. Males, having lower SM concentrations than fe-
males, showed higher LPC concentrations, which is in
accordance with LPCs being associated with higher LDL
and lower HDL. The sex difference may also explain
previous findings of decreased LPC concentrations in
association with obesity, as LPC are higher in males than
in females [20, 21].
Although higher circulating LPC levels in the blood
have been predominantly associated with LCAT activity
[22], higher levels of LPC have also been associated with
phospholipase A2 (PLA2) activity. This enzyme mainly
associates with LDL and hydrolyses the fatty acid at the
sn-2 position from phospholipids, leading to a LPC and
a non-esterified fatty acid. This reaction by LPC by
PLA2 is thought to play an important role in the early
onset of cardiovascular diseases [23]. There is some evi-
dence that PLA2 activity is increased in males compared
with females, in accordance with our finding that LPCs
were associated with male sex [24].
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Association with Triacylglycerol: Beta and Significance Test
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Association with Waist Circumference: Beta and Significance Test
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Fig. 3 Barplots of the β coefficients from the sex stratified regression models with MetS factors (WC, HDL-C, TG and sysBP) as outcome and single
metabolite concentration as predictor, adjusted for ethnicity, physical activity, sedentary behaviour, dietary patterns, smoking, and alcohol consumption.
Significance (*): FDR-corrected significant difference of the effect size between the sex groups. Confidence intervals: False coverage rate
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The difference in PC and SM levels between males and
HC and non-HC females is likely related to the different
distribution of lipoprotein species and their associated
metabolic consequences. This may also explain some of
the differences associated with HDL which is enriched in
PC containing polyunsaturated fatty acids [25].
Serine was significantly higher in females. Together with
palmitoyl-CoA concentrations, serine is the initial and
rate-limiting metabolite in the metabolism of sphingolipids.
We found that AA and especially branched chain amino
acids (BCAA) concentrations were higher in males than in
HC or non-HC females. BCAA and associated metabolites
have been shown to associate with insulin resistance, car-
diovascular disease and female sex hormones [26].
BCAA have been shown to be important in muscle
metabolism, which could explain the significantly posi-
tive association of leucine with male sex rather than HC
or non-HC females, since males have a higher percentage
of lean body mass including muscle mass than females
[27]. Testosterone is long known as an anabolic hormone
linked to AA metabolism [28]. In a study in elderly men,
testosterone supply led to increased strength and lean
body weight [28]. In general the differences between males
and females in the metabolome likely reflect differences in
lipid and AA metabolism.
Hormones and hormonal contraceptives
The majority of HC provide the two hormones estrogen
and progesterone, which influence AA and lipid metab-
olism [28–39]. We found that HC females have de-
creased free Carn and acyl-Carn levels together with
decreased AA levels. Previous reports show female free
Carn and acyl-Carn levels decrease significantly upon
reaching fertile age [30]. It was suggested that estrogen
levels might be the reason.
Furthermore, estrogen is associated with an increased
availability of fatty acids by lipolysis and also decreases
carbohydrate metabolism [19, 31].
A recent study showed that a decrease in estrogen
enhances the accumulation of visceral fat in women
through Aldehyde dehydrogenase 1 family, member A1
(aldh1a1), but the effect of the enzyme was not relevant
in men, supporting sex differences in lipid metabolism
driven by hormones [32].
Our observation of reduced concentrations of some
NEFA species in males compared to non-HC females and
especially HC females could be due to the higher testoster-
one levels in males [33]. Higher insulin concentrations are
known to associate with lower NEFA levels that associate
with a lower β-oxidation in the fasting state and therefore
also lower acyl-Carn levels, as carrier of fatty acids.
Estrogen and estradiol have been shown to increase
HDL-C blood concentrations, which is a protective
marker for cardiovascular diseases. This could, in part,
explain the increased risk of cardiovascular diseases in
women after menopause [34]. In accordance with our
findings, HC use has been associated with higher HDL-C
and low-density lipoprotein-cholesterol (LDL-C) (higher
than in males in our data), TG (lower in HC females com-
pared to that in males and non-HC females in our data)
concentrations [34]. This could explain the higher PC and
SM concentrations in HC females compared to those in
males and non-HC females, as they are the most abundant
phospholipids in lipoproteins [35].
Some estrogen compounds have been shown to not only
decrease concentrations of stearic acid but also, amongst
others, increase palmitic acid in PC in the serum [38]. The
lower levels of LPCa C16:0, LPCa C18:0 and LPCa C18:1
in HC females compared to non-HC females could be a
reflection of that, since they potentially occur after cleav-
ing a fatty acid from PCs by LCAT activity.
MetS dependent differences
Males in our study have a more adverse metabolic pro-
file than non-HC females and HC females, with respect
to WC, sysBP and TG, HDL-C and glucose concentra-
tions and also differences in the relationships between
these components and different metabolites, for example
LPC concentrations between males and either HC or
non-HC females.
HC and non-HC females mainly differed in SM and
PC concentrations. WC, TG and HDL were associated
with increased LPC concentrations that are also differ-
ently elevated between males and HC and non-HC fe-
males. This is in keeping with the finding that LPC
concentrations have been associated to WC in other
studies and highlights the importance of our findings.
HDL levels are associated with LCAT, an enzyme that
leads to the formation of LPC [36]. In our study, males
had higher levels of LPC and lower levels of HDL-C
than females.
HDL is known to contain a lower SM/PC ratio than
LDL, which could be a reason for HDL being mainly as-
sociated with PC and LPC species in our study [37]. The
β coefficient for the association between LPC levels and
components of the MetS was higher in females than in
males; irrespective of whether it was a positive (sysBP,
TG, HDL) or negative (TG, WC, HDL) association. This
suggests a more negative effect of LPC in females than
in males, possibly due to the fact, that males already
have higher levels of LPC.
In our study SM had a strong association with high
levels of components of the MetS in males and in HC or
non-HC females. But in general, SM concentrations
were higher in females (HC and non-HC) than in males.
To our knowledge there are no other studies that have
performed a comprehensive metabolomics analysis exam-
ining sex differences in relation to components of the
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MetS. Newbern et al. reported sex differences in insulin
resistance in adults in their metabolomics study, although
these were mainly in BCAAs and their by-products short-
chain acyl-Carn [15].
Because of the young age of 20 years of the partici-
pants, the analysis of this cohort is valuable for future
lifestyle and other prevention strategies in this age
group. Additionally, the sample size is exceptionally high
with more than 1000 participants. Studies like ours pro-
vide some insight into the possible mechanisms for the
differences in the prevalence of diseases between sexes.
These data are also important in assisting intervention
and metabolomics studies conducted in the future.
The limitations of our study are that we do not have
blood sex hormone concentrations or any information
on the time of the estrous cycle, so the focus of this
study is hypothesis generation. It is an observational co-
hort study with a cross-sectional analysis, which does
not allow for interpretations of the directions of associa-
tions. Additionally, we had only plasma and no cell sam-
ples to measure and interpret metabolic changes, and we
did not have separated lipoprotein species.
Conclusions
This study has shown clear differences between plasma
metabolite concentrations in males and HC or non-HC
females, especially in LPC, SM and PC, which have been
shown to associate with obesity in other studies [7, 21, 38].
Further, the association of these metabolites differed be-
tween sexes with components of the MetS, which means
that development of diseases like obesity and diabetes may
differ between the sexes, potentially mediated by sex hor-
mones. Our findings highlight the importance of consider-
ing sex differences when conducting a metabolomics
study, and the need to account for the effect of HC usage
in females in future studies. The latter finding could be of
importance for early programming or pregnancy studies, as
the use of HC leads to a hormonal state in the body similar
to pregnant women [29, 39]. To our knowledge this is the
first comprehensive analysis demonstrating differences in
metabolomics between males and females, as well as the
effect of HC use. Additionally, we show that the association
between metabolomics markers and components of the
MetS are significantly different between males and females.
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